Alveolar Type II Cells Possess the Capability of Initiating Lung Tumor Development

doi:10.1371/journal.pone.0053817

PLoS One. 2012; 7(12): e53817.

Published online 2012 December 20. doi: 10.1371/journal.pone.0053817

PMCID: PMC3527621

Alveolar Type II Cells Possess the Capability of Initiating Lung Tumor Development

Chuwen Lin, Hai Song, Cecilia Huang, Erica Yao, Rhodora Gacayan, Shan-Mei Xu, and Pao-Tien Chuang^*

Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, United States of America

Edward Morrisey, Editor

University of Pennsylvania School of Medicine, United States of America

* E-mail: pao-tien.chuang/at/ucsf.edu

Competing Interests: The authors have declared that no competing interests exist.

Conceived and designed the experiments: CWL HS CH EY PTC. Performed the experiments: CWL HS CH EY RG PTC. Analyzed the data: CWL HS CH EY PTC. Contributed reagents/materials/analysis tools: CWL HS CH EY SMX. Wrote the paper: CWL CH EY PTC.

Received October 12, 2012; Accepted December 3, 2012.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Identifying cells of tumor origin is a fundamental question in tumor biology. Answers to this central question will not only advance our understanding of tumor initiation and progression but also have important therapeutic implications. In this study, we aimed to uncover the cells of origin of lung adenocarcinoma, a major subtype of non-small cell lung cancer. To this end, we developed new mouse models of lung adenocarcinoma that enabled selective manipulation of gene activity in surfactant associated protein C (SPC)-expressing cells, including alveolar type II cells and bronchioalveolar stem cells (BASCs) that reside at the bronchioalveolar duct junction (BADJ). Our findings showed that activation of oncogenic Kras alone or in combination with the removal of the tumor suppressor p53 in SPC⁺ cells resulted in development of alveolar tumors. Similarly, sustained EGF signaling in SPC⁺ cells led to alveolar tumors. By contrast, BASCs failed to proliferate or produce tumors under these conditions. Importantly, in a mouse strain in which Kras/p53 activity was selectively altered in type II cells but not BASCs, alveolar tumors developed while BADJs retained normal architecture. These results confirm and extend previous findings and support a model in which lung adenocarcinoma can initiate in alveolar type II cells. Our results establish the foundation for elucidating the molecular mechanisms by which lung cancer initiates and progresses in a specific lung cell type.

Introduction

Non-small cell lung cancer (NSCLC) accounts for ~85% of lung cancers and most patients present with advanced disease [1]. Despite the investment of an enormous amount of effort and resources in the past few decades, the treatment options remain very limited for advanced or recurrent NSCLC [2], [3]. For inoperable tumors, the standard treatment consists of various combinations of chemotherapy, radiotherapy and targeted therapies [4]. Improvements in prognosis have been modest, with an overall 5-year survival rate of only 10–15%. This is in sharp contrast to the drastically improved 5-year survival rates in patients afflicted by many other types of solid tumors such as breast or prostate cancer. These achievements are due to early diagnosis and effective treatment. This highlights an urgent need for basic research to identify the cells from which lung cancer originates and uncover the molecular basis of tumor development in order to design new therapies [5]–[8].

Based on mutation profiles identified in human NSCLC [9], several mouse models of NSCLC have been created [10]–[15]. A widely used model combines p53 ablation with Kras activation in the mouse lung epithelium [16]–[18]. These mice developed lung adenocarcinoma (the major subtype of NSCLC) [19] that recapitulates critical aspects of human NSCLC. However, this approach relies on inactivation of p53 and activation of Kras in the lung epithelium globally [20]. It does not allow for identifying the cells of origin of NSCLC or isolating a pure population of tumor cells at distinct stages of tumor development for genome-wide analysis. Addressing these issues requires additional mouse models in which oncogenes and tumor suppressors can be selectively manipulated in a given cell population to test their role in tumor development.

Another important mouse model of NSCLC is based on the finding that a fraction of patients whose tumors harbor mutations in the gene encoding the epidermal growth factor receptor (EGFR) [21], [22] are responsive to tyrosine kinase inhibitors (TKIs) that block EGF signaling. Mice carrying various EGFR mutations found in human lung cancer develop lung tumors [23], [24], providing an appropriate animal model for studying NSCLC development and drug resistance. Likewise, the cells of origin of lung tumors in these systems have not been rigorously addressed due to the lack of tools that enable selective manipulation of gene activity in a particular lung cell type.

Investigating the cells of origin of lung cancers will provide new insight into the molecular basis of tumor initiation and progression. It is possible that human lung cancers that originate from different cell types possess characteristic mutation profiles and behaviors. Distinct cell types in the airway and alveoli [25] that fulfill requisite physiological functions of the lung are also candidates as the initiating cells of adenocarcinoma [26]. Secretory non-ciliated Clara cells in the bronchioles are interspersed with ciliated cells and neuroendocrine cells, whereas type I and type II cells line the gas-exchange epithelium of the alveoli. Bronchioalveolar stem cells (BASCs) [27] express markers for Clara cells (CC10) and type II cells (SPC) and are located at the bronchioalveolar duct junction (BADJ) where terminal bronchioles connect with the alveoli. The physiological function of BASCs remains unclear [28]. Clara cells, BASCs and type II cells possess proliferative potential in various conditions and could potentially accumulate mutations in these processes to initiate tumor development. Nevertheless, it remains uncertain whether tumor development can also begin in non-proliferative, differentiated cell types or transformation is largely confined to cells with progenitor potential. In this study, we utilize mouse lines that allow the manipulation of gene activities in alveolar type II cells and BASCs to test these ideas. Our results support a model in which lung adenocarcinoma can initiate in type II cells. These studies provide the basis for further investigation to uncover the molecular mechanisms of tumor development and progression.

Results

Inducible Expression of CreER Recombinase or Activation of rtTA Under the Control of the SPC Promoter Allows the Manipulation of Gene Activity in SPC⁺ cells Including Alveolar Type II and BASC cells

Proliferation of alveolar type II cells significantly increases following lung injury. Type II cells also have the potential to generate type I cells, which are responsible for gas exchange in the alveoli [25]. These progenitor-like properties render type II cells a prime candidate for initiating lung adenocarcinoma. To regulate gene activity in type II cells, we generated two mouse lines by (1) introducing CreER into the endogenous mouse SPC (Sftpc; surfactant associated protein C) locus via gene targeting [29] and (2) introducing rtTA into an SPC-containing bacterial artificial chromosome (BAC) for producing transgenic mice. This is based on the finding that SPC constitutes the major peptide in type II cells and is not present in other lung cell types [30] except the SPC⁺CC10⁺ BASCs at the BADJ. The resulting mouse lines are designated SPC^CreER (Fig. 1A) and SPC^rtTA (Fig. 1B) respectively in this study and they enable control of gene activity in SPC-expressing type II cells and BASCs.

Figure 1

SPC^CreER and SPC^rtTA mice allow manipulation of gene activities in alveolar type II cells.

CreER encodes a fusion protein of Cre recombinase and estrogen receptor (ER) and is activated by tamoxifen (TM) [31]. Thus, tamoxifen administration to SPC^CreER mice provides an efficient way to control Cre activity in a temporal- and spatial-specific manner. For example, tamoxifen injection into adult SPC^CreER mice should allow exclusive Cre expression in SPC-expressing cells, including type II cells and BASCs, after lung development is completed. Selective, inducible Cre expression in conjunction with Cre-lox technology offers a unique opportunity to regulate gene activity in type II cells and BASCs. We tested the efficiency and specificity of CreER expression in SPC^CreER mice by breeding SPC^CreER mice with several reporter mouse lines, including R26R [32] and ROSA26^mTmG [33]. Cre activation would result in eGFP expression from the ROSA26^mTmG allele by removing sequences that block its expression. For example, we found that daily injection of tamoxifen (0.25 mg/g body weight) for four to six times into SPC^CreER/+; ROSA26^mTmG/+ adult mice led to efficient expression of CreER, resulting in eGFP expression in SPC⁺ type II cells (Fig. 1F) and BASCs (Fig. 1I). A low level of CreER activity without TM injection in type II cells was noted (Fig. 1D, 1E) and leaky expression of CreER appears to vary from animal to animal. The specificity of CreER expression in type II cells was demonstrated by the observation that few SPC(–) cells were labeled by eGFP expression in SPC^CreER/+; ROSA26^mTmG/+ lungs (Fig. 1J). These findings indicate that CreER expression from SPC^CreER mice is specific and sufficient to permit manipulating gene activity in SPC-expressing cells.

The tetracycline inducible rtTA (Tet-On) system consists of two major elements: rtTA and TRE (tet response element; denoted as tetO) [34]. In the absence of doxycycline (dox), rtTA does not bind or binds weakly to TRE and the gene placed under TRE control is not transcribed. However, in the presence of the inducing agent dox, rtTA binds to TRE, which in turns activates transcription of TRE-controlled genes. We introduced rtTA into the SPC locus and tetO-Cre into the Nudt18 locus contained within a single BAC clone (designated SPC^rtTA for simplicity) and produced the transgenic mouse line SPC^rtTA by pronuclear injection [35] (Fig. 1B). tetO-Cre was introduced into a separate genomic locus to avoid any potential interference with rtTA. When dox food was used continuously for SPC^rtTA/+; R26R/+ or SPC^rtTA/+; ROSA26^mTmG/+ mice, extensive labeling of type II cells was observed (Fig. 1H, 1L) in contrast to the spotty labeling in SPC^rtTA/+; R26R/+ or SPC^rtTA/+; ROSA26^mTmG/+ mice without dox (Fig. 1G, 1K). This suggests that rtTA expression from SPC^rtTA/+ mice should enable manipulating gene activity in SPC⁺ cells, including all genes that are placed under TRE (tetO) control.

Activating Kras Alone or in Combination with p53 Removal in Murine SPC⁺ cells Led to Non-small Cell Lung Cancer (NSCLC) Development in Alveoli

Loss of p53 and activated Kras mutations are frequently found in human NSCLC [9]. This prompted several groups to develop a mouse model of NSCLC through global inactivation of p53 and activation of Kras (G12D mutation) in the lung epithelium, which was achieved via intrabronchial injection of adenoviral Cre [16]–[18]. This mouse model of NSCLC recapitulates critical aspects of human NSCLC, validating the use of mouse models for understanding human NSCLC [12]. However, this approach carries several important caveats, including the side effects of anti-inflammatory agents used to suppress adenovirus-induced inflammation, the inconsistent delivery and expression of adenoviral Cre that could result in variable tumor development and perhaps most importantly, the inability to pinpoint the cell types that initiate transformation.

To address these issues, we employed the SPC^CreER mouse line to activate Kras and inactivate p53 in SPC⁺ cells. We took advantage of the widely used Kras^LSL-G12D and p53^f alleles. Kras^LSL-G12D is converted into activated Kras^G12D by Cre, while the conditional p53^f allele is converted into a null allele in the presence of Cre. This offers a precise genetic system to manipulate p53 and Kras exclusively in SPC⁺ cells. We bred mice to produce SPC^CreER/+; Kras^LSL-G12D/+ and SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice and administered tamoxifen to these adult animals. Lungs were collected at different time points after TM injection for analysis.

By 18 weeks after TM injection, SPC^CreER/+; Kras^LSL-G12D/+ mice developed numerous tumors in the alveoli, largely adenomas and a small number of cells with features of malignant transformation (Fig. 2B, 2D), while the airways and BADJs retained normal architecture (Fig. 2A, 2C, 2E, 2G). These tumors stained positive for SPC (negative for CC10 and Sox2) (Fig. 2F, 2H, 2I) and were morphologically similar to those produced in a lung cancer model in which adenoviral Cre was used to induce Kras^G12D expression [16]–[18]. Tumor cells exhibited high proliferation (Fig. 2J). This phenotype is completely penetrant, follows a defined time sequence and does not appear to be affected by genetic background. We noted that a significant fraction of tumors was found in close proximity to the airway or BADJ or the surface of the lung. Interestingly, the BADJ itself did not contain hyperplastic lesions or tumors.

Figure 2

Induction of alveolar lung tumors in mice with activated Kras alone or in combination with loss of p53 in SPC-expressing cells.

Compared to SPC^CreER/+; Kras^LSL-G12D/+ mice at the same stage, SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice exhibited a more severe phenotype in terms of tumor size and tumor growth and grade as a result of p53 elimination in addition to Kras activation. At 3–4 weeks after TM injection, several small adenomas of papillary nature could already be found in the alveoli of SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice (Fig. 2L). These lesions expressed SPC but not CC10 (Fig. 2P) or Sox2 (not shown). At 10 weeks after TM injection, large tumors were widespread in the alveoli and they exhibited features characteristic of higher grade lung tumors such as the presence of enlarged pleomorphic nuclei, aberrant mitosis and tumor giant cells (Fig. 2N). Tumor cells were also highly proliferative and invasive (Fig. 2T). In fact, many SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice did not survive beyond this stage due to the heavy burden of lung tumors. In mice that did survive to 13 weeks after TM injection, their lungs contained adenocarcinoma in the alveoli consisting of cells with features of malignant transformation surrounded by stromal cells. Similarly, all tumors examined stained positive for SPC (Fig. 2R) but not CC10 (Fig. 2R) or Sox2 (Fig. 2S). Since Sox2 is expressed in the conducting airway (including cells at the BADJs) and not SPC⁺ cells in the alveoli, lack of Sox2 expression in lung tumors would be consistent with a tumor origin from type II cells. Surprisingly, BADJs appeared normal in SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice at all time points examined (Fig. 2K, 2M, 2O, 2Q) even though SPC^CreER was expressed in a significant fraction of BASCs in BADJs (Fig. 1I, 1J). We performed a careful analysis of BASC proliferation in both SPC^CreER/+; Kras^LSL-G12D/+ and SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice injected with tamoxifen. While extensive type II cell proliferation was observed (Fig. 2U–X), proliferating BASCs were rarely found (Fig. 2U–X) when Kras was activated either alone or in conjunction with p53 removal. BASC proliferation was assessed at eight days, three weeks, six weeks, ten weeks and thirteen weeks after TM injection and similar results were obtained. Interestingly, proliferation of SPC⁺ type II cells that carry p53 and Kras mutations can be detected in just a few days after TM administration (Fig. 2Y–Z and 2A’–B’). Taken together, our findings suggest that alveolar tumors induced by Kras/p53 perturbation were derived from alveolar type II cells and not BASCs. They support a model in which SPC-expressing type II cells proliferate in response to oncogene activation/tumor suppressor removal and initiate tumor development.

Leaky SPC^CreER Expression without Tamoxifen Injection was Found in Some Alveolar Type II Cells and Not BASCs in Certain SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice, Resulting in Proliferation and Transformation of Alveolar Type II and Not BASC cells

We noticed spotty expression of CreER in some SPC^CreER; ROSA26^mTmG mice without tamoxifen injection (Fig. 1D, E). Interestingly, leaky CreER expression was only detected in alveolar type II cells (Fig. 3A) and not in BASCs or other lung cell types (Fig. 3B). We took advantage of this observation to further test the cells of origin of lung adenocarcinoma developed in SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice without tamoxifen injection. This would allow us to directly follow the fate of type II cells carrying Kras/p53 mutations without the complication of BASCs.

Figure 3

Leaky expression of SPC^CreER in alveolar type II cells and not BASCs is associated with alveolar tumors while BADJs retain normal architecture.

We performed a careful immunohistochemical analysis of lungs collected from SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice without tamoxifen injection. These mice with leaky CreER expression without TM injection survived a few more months than those injected with TM. Similar to SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice injected with tamoxifen, invasive lung adenocarcinomas observed in SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice with leaky CreER expression localized to the alveoli (Fig. 3D, 3E). Tumor cells expressed type II cell marker (SPC) and were highly proliferative (Fig. 3E). BADJs, where BASCs reside, retained normal architecture (Fig. 3C) in SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice with leaky CreER expression and no obvious proliferation was observed at the BADJ (Fig. 3F). This provides additional evidence to support the notion that alveolar type II cells can be the initiating cells for lung adenocarcinoma.

Activating EGFR in Murine SPC⁺ cells Led to Tumor Development in Alveoli

To further test the notion that alveolar type II cells can be the originating cells for NSCLC, we utilized our SPC^rtTA mice to activate EGF signaling in SPC⁺ cells. We bred mice to produce SPC^rtTA/+; tetO-EGFR^L858R animals. The tetO; EGFR^L858R mice harbor a transgene in which a mutant form of EGFR (EGFR^L858R) is under the control of tetO; thus EGFR^L858R expression can be induced upon doxycycline (dox) administration [23]. Importantly, the L858R mutation in EGFR is frequently found in human adenocarcinoma and is known to confer ligand-independent EGF signaling [36], [37]. SPC^rtTA/+; tetO-EGFR^L858R animals provide a means to regulate EGF signaling in cells that express rtTA.

In the absence of dox, the lung morphology of SPC^rtTA/+; tetO-EGFR^L858R mice (Fig. 4A, 4B) was similar to that in wild-type mice. This suggests that even if low levels of EGFR^L858R were expressed in some SPC⁺ cells in the absence of dox, they are insufficient to cause any phenotypes. Consistent with this, only spotty labeling of SPC⁺ cells by R26R or ROSA26^mTmG reporters was observed in the absence of dox as described above (Fig. 1G, 1K), reflecting a low degree of leaky rtTA expression. By contrast, dox administration promoted rtTA binding to tetO and activated EGFR^L858R in SPC-expressing cells. We found that after 12 weeks of continuous dox administration, SPC^rtTA/+; tetO-EGFR^L858R mice developed widespread tumors in the alveoli (Fig. 4C, 4D) but not in other parts of the lung, including the airway (Fig. 4H) and BADJ (Fig. 4I). No hyperplasia was detected in the airways or BADJs (Fig. 4C, 4D) and proliferating BASCs were rarely found. Tumor cells in SPC^rtTA/+; tetO-EGFR^L858R mice stained positive for SPC and negative for CC10 (Fig. 4G, 4J), and were highly proliferative (Fig. 4L) compared to non-tumor tissues (Fig. 4K). In conjunction with studies using SPC^CreER, these results provided additional evidence to support the idea that NSCLC can be initiated in SPC⁺ type II cells. Interestingly, alveolar tumors regressed after dox withdrawal (Fig. 4E, 4F), suggesting that neoplasia is dependent on active EGFR signaling, consistent with previous reports [23]. This genetic system thus offers the advantage of studying the molecular process of tumor regression and resistance.

Figure 4

Induction of alveolar lung tumors in mice with activated EGF signaling in SPC⁺ cells.

Mouse Alveolar Tumors Induced by Kras/p53 Mutations are Associated with Notch Pathway Activation

As a first step toward understanding the molecular mechanisms that underlie tumor development and confer tumor properties, we investigated whether major signaling pathways were perturbed in lung tumors developed in SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice. We extracted RNA from dissected tumors and adjacent non-tumor tissues and performed qPCR analysis to examine the expression of target genes for major signaling pathways. Interestingly, we found that Notch signaling was consistently upregulated in tumor versus non-tumor tissues (Fig. 5A). By contrast, several other major signaling pathways, including the Platelet-derived growth factor (PDGF), Wnt, Bone morphogenetic protein (Bmp) and Hedgehog (Hh) pathways, showed modest or no apparent changes in target gene expression in tumor tissues compared to non-tumor tissues (Fig. 5A). Interestingly, expression of Itgb4 (integrin beta 4) was also increased in mouse lung tumor tissues (Fig. 5A) as well as in human non-small cell lung cancer cell lines (Fig. 5B). Notch signaling has been associated with survival of lung adenocarcinoma cells in vitro [38] and tumor metastasis [39]. Our findings suggest that activated Notch signaling in response to Kras/p53 mutations could be involved in tumor development or confer tumor properties. The genetic system we developed provides an ideal setting to isolate tumor cells at different stages of tumor development and ask how Notch signaling controls tumor initiation, progression and invasion/metastasis. These studies will provide mechanistic insight into the roles of major signaling pathways in lung tumor development.

Figure 5

Analysis of major signaling pathways in mouse Kras/p53 tumors and marker expression in human lung cancer cell lines.

Discussion

Through the development of new genetic tools in mice, we provide strong evidence to support the notion that human NSCLC can originate from alveolar type II cells. Our results confirm and extend the findings in a recent report [40], which primarily analyzed mice carrying Kras mutations. No evidence was presented in the published article [40] to demonstrate tumor invasion or metastasis. It is worth noting that earlier reports using adenoviral-Cre to infect lung epithelium globally showed that mice carrying the Kras mutation and one loss-of-function allele of p53 in the lung exhibited phenotypes similar to mice carrying the Kras mutation alone [41]. This suggests that loss of both copies of p53 is critical for invasive tumors to develop. Our experimental setting enabled us to achieve simultaneous Kras activation and p53 ablation. As a result, tumor invasiveness was observed in Kras/p53 mutants but not in mice carrying activated Kras alone under our experimental conditions. Importantly, taking advantage of the leaky expression of our SPC^CreER line only in alveolar type II cells but not in BASCs, we were able to attribute lung adenocarcinoma developed in these mice to type II cells and not BASCs. Taken together, these new findings strongly support the idea that development of lung adenocarcinoma (beyond adenoma or carcinoma in situ) originates from SPC⁺ alveolar type II cells.

A previous report [23] relied on a CCSP-rtTA transgene to investigate how EGFR mutations in different lung cell types could influence tumor development. The CCSP-rtTA transgene utilizes a short fragment of the rat CCSP promoter to drive rtTA expression. The short rat CCSP promoter does not recapitulate mouse CCSP (CC10) expression and displays significant leaky expression in SPC-expressing cells, raising the possibility that it is expressed in BASCs. How EGFR mutations affect BASC proliferation/transformation was not addressed in previous work [23]. Our SPC-rtTA mouse line in which rtTA is under the control of the endogenous SPC promoter provides the first mouse model to assess the effects of EGFR mutations on transforming SPC⁺ type II cells.

While our results suggest that NSCLC could initiate in type II cells, the exact nature of tumor-initiating cells requires further investigation. Without tracing the early events at the molecular level, it is not possible to decipher how differentiated type II cells that carry oncogenic mutations undergo progressive transformation. It is possible that all SPC-expressing type II cells share a similar potential of being transformed. Alternatively, tumors may only initiate in a small population of uncharacterized type II cells, for instance, those expressing low levels of SPC and presumably possessing proliferative potential in various conditions [42] or those residing at specific anatomical locations. Without markers currently available to define subpopulations of type II cells, it is not possible to assess the transformation potential of distinct subpopulations of type II cells, if they do exist. It is also uncertain how the transformation potential of type II cells is compared to other lung epithelial cell types such as Clara cells, BASCs, ciliated cells, goblet cells and type I cells under various genetic perturbations. Perhaps, distinct cell types are susceptible to specific insults and a systematic investigation is required to delineate the molecular basis of proliferative potential among distinct lung cell types or populations. These studies would shed light on the source of heterogeneity or subtypes of NSCLC, the very properties of which could originate from distinct cell types carrying different mutation profiles. Finally, we cannot rule out the possibility that cells with altered p53 and Kras activities may exert non-cell autonomous effects on neighboring cells and induce tumor development in these cells containing wild-type p53 and Kras.

We found some degree of leakiness present in both SPC^CreER and SPC^rtTA mouse strains that we used to manipulate gene activity in type II cells. In particular, more sensitive reporter lines (e.g., ROSA26^mTmG) appear to detect even very low levels of leaky expression. In some cases, variations in background expression among individual mice were also noted. Consistent with these findings, when leaky CreER expression reached a critical threshold in SPC^CreER/+; Kras^LSL-G12D/+ or SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice, cell hyperplasia and even tumor development was observed without TM administration albeit at a lower frequency than in mice injected with TM. Interestingly, even in mice in which leaky CreER expression led to tumor development, tumors were never detected at the BADJ. By contrast, SPC^rtTA/+; tetO-EGFR^L858R mice without dox do not develop hyperplasia or tumors. This probably reflects differential sensitivities of type II cells to diverse perturbations.

Given that SPC^CreER confers the ability to manipulate gene activity in BASCs, it is somewhat surprising that hyperplasia at the BADJ was not observed in SPC^CreER/+; Kras^LSL-G12D/+ or SPC^CreER/+; p53^f/f; Kras^LSL-G12D/+ mice when CreER is activated by TM. This raises the possibility that BASCs are not as sensitive to Kras/p53 perturbation as other SPC-expressing cells. Similarly, active EGF signaling in SPC-expressing cells only led to alveolar tumor development and not BASC hyperplasia or neoplasia. Since BASCs express both SPC and CC10, it would be interesting to compare the transformation potential between BASCs and Clara cells. Whereas our results do not provide evidence to support a role for BASCs in tumor development, it is conceivable that additional genetic perturbation not utilized in this study may be required to transform BASCs. It is also possible that a longer time period is needed for tumors to develop in BASCs. This is consistent with the observation that human lung tumors usually develop after many years or even decades of repeated epithelial injury such as from cigarette smoking. Though BASC proliferation is rare in our experimental setting, we cannot formally rule out the possibility that BASCs can be transformed, expanded and differentiated into type II-like cells. Lineage-tracing studies in which Kras/p53 mutant BASCs and type II cells are labeled and followed during early tumor development will provide new insight into this important issue.

Human NSCLC is a heterogeneous group of diseases that share common histology but carry different mutations and perhaps even originate from different cell types [43]. For instance, some NSCLC cell lines express markers of alveolar type II cells (Fig. 5B). By contrast, the mouse models we developed likely mimic only a subset of human lung cancer. A key feature of the system is its ability to mark alveolar type II cells and trace the early events of tumor development. Equally important is the opportunity that this system offers to isolate transformed type II cells induced by different genetic perturbations at various stages of progression for whole-genome analysis (including RNA-Seq and Exome sequencing). These studies will yield key insight into the molecular mechanisms of transformation. Such analysis will also provide candidates for early diagnosis and targeted therapies of NSCLC [44]. We speculate that our mouse model offers a defined genetic system with a shorter time frame of tumor development in which fewer mutations are accumulated in the process of transformation compared to human lung cancer. Employing mouse models would facilitate the identification of relevant candidates for diagnosis and treatment through comparative genomic analysis between human and mouse tumors.

Materials and Methods

Mice

All animal work was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee at the University of California, San Francisco.

To produce the SPC^CreER mouse line, the translational start ATG in the mouse SPC genomic locus was replaced with a CreER-FRT-PGK-Neo-FRT cassette through gene targeting in E14 embryonic stem (ES) cells. The FRT-PGK-Neo-FRT cassette was subsequently removed by crosses with FLPe mice [45].

The SPC^rtTA mouse line harbors an engineered bacterial artificial chromosome (BAC) in which rtTAtPA was placed at the translational start ATG of the SPC genomic locus and tetO-Cre was inserted at the translational start ATG of the Nudt18 genomic locus. To generate the SPC^rtTA BAC, an rtTAtPA targeting construct containing homologous arms to the SPC genomic locus was introduced by the GalK cloning system [46] into a mouse BAC clone (RP23-247J9; CHORI). RP23-247J9 spans the SPC and Nudt18 genomic regions with the SPC gene centering on RP23-247J9. After screening correctly targeted clones at the SPC locus, the recombined BAC underwent a second recombination to introduce tetO (TRE-Tight)-Cre to the Nudt18 locus. The Nudt18 gene is located ~57 kb upstream of the translational start ATG of SPC. BAC DNA was linearized with PI-SceI and introduced into CD-1 zygotes by pronuclear injection to produce transgenic mice.

p53 floxed (FVB.129-Trp53^tm1Brn), Kras^LSL-G12D (B6.129-Kras^tm4Tyj) and tetO-EGFR^L858R (B6; CBA-Tg(tetO-EGFR*L858R)56Hev) mice were obtained from the NCI Mouse Repository. ROSA26^mTmG (Stock Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/J) and R26R (B6; 129S4-Gt(ROSA)26Sor^tm1Sor/J) mice were obtained from Jackson Laboratory.

Tamoxifen Administration

Tamoxifen (TM) (Sigma) was dissolved in Mazola corn oil to make a stock solution of 50 mg/ml. TM (0.25 mg/g body weight) was injected into adult mice daily for four to six days. Lungs were collected for analysis at indicated time points.

Histology, Immunohistochemistry and β-galactosidase Staining

Mouse lungs were inflated with 1 ml of 2% paraformaldehyde (PFA) and fixed for 4 hrs-overnight at 4°C in 2% PFA. After dehydration and processing, lungs were embedded in paraffin for sectioning and immunohistochemistry. All the tissues collected were sectioned at 6 µm thickness for histological analysis. Paraffin sections were stained with the following primary antibodies: chick anti-GFP (1 [ratio]

200, Abcam), goat anti-CC10 (1 [ratio]

200, Santa Cruz), rabbit anti-proSP-C (1 [ratio]

400, Millipore), hamster anti-T1α (1 [ratio]

200, Developmental Studies Hybridoma Bank), mouse anti-Ki67 (1 [ratio]

200, BD) and goat anti-Sox2 (1 [ratio]

200, Santa Cruz). Secondary antibodies and conjugates used include: donkey anti-chick DyLight 488 (1 [ratio]

1,000; Jackson ImmunoResearch Laboratories), donkey anti-rabbit Alexa Fluor 594 (1 [ratio]

1,000; Life Technologies), donkey anti-goat Alexa Fluor 594 or 647 (1 [ratio]

1,000; Life Technologies), donkey anti-mouse Alexa Fluor 594 or 647 (1 [ratio]

1,000; Life Technologies), and DAPI (1 [ratio]

10,000; Sigma). For biotinylated secondary antibodies (goat anti-rabbit, 1 [ratio]

1,000, donkey anti-goat, 1 [ratio]

1,000 and horse anti-mouse, 1 [ratio]

1,000, Jackson ImmunoResearch Laboratories), the signal was detected using HRP-conjugated streptavidin (1 [ratio]

1,000, Vector Laboratories) in combination with either the chromogenic substrate DAB (Vector Laboratories) or fluorogenic substrate Alexa Fluor 594 tyramide (1 [ratio]

100, TSA kit, Perkin-Elmer). Antibodies against Ki67 may require the biotin-streptavidin amplification step for optimal signal detection. Fluorescent images were acquired using a SPOT 2.3 CCD camera connected to a Nikon E1000 epifluorescence microscope. Adjustment of RGB histograms and channel merges were performed using SPOT Advanced software or ImageJ. Confocal images were captured on a Leica laser-scanning confocal microscope. Multiple optical sections were obtained to distinguish cell boundaries. For X-gal staining, lungs were inflated with 1 ml of 1% PFA, 0.2% gluteraldehyde and fixed 1 hr at 4°C in 1% PFA and 0.2% gluteraldehyde. To detect β-galactosidase activity, whole lungs or frozen sections (10 µm) were stained in X-gal staining solution following standard procedures.

Analysis of Target Gene Expression for Major Signaling Pathways in Mouse Lung Tumors and Lung Marker Expression in Human Lung Cancer Cell Lines

Tumor and adjacent non-tumor tissues were microdissected from the mouse lungs. Human lung cancer cell lines were purchased from ATCC. Total RNA was extracted using Trizol (Invitrogen) and RNeasy Mini Kit (Qiagen) and subsequently reverse-transcribed to cDNA using the SuperScript Kit (Invitrogen). Quantitative PCR (qPCR) was carried out on the ABI Prism 7900HT Sequence Detection System.

The following primers for mouse genes were used: Ccnd1 F: 5′GCAGAAGGAGATTGTGCCATCC3′; CCnd1 R: 5′AGGAAGCGGTCCAGGTAGTTCA3′; Notch1 F: 5′GCTGCCTCTTTGATGGCTTCGA 3′; Notch1 R: 5′CACATTCGGCACTGTTACAGCC3′; Hes1 F: 5′GGAAATGACTGTGAAGCACCTCC3′; Hes1 R: 5′GAAGCGGGTCACCTCGTTCATG3′; Itgb4 F: 5′ACACAAGCTCCAGCAGACGAAG3′; Itgb4 R: 5′TCCACCTGCTTCTCTGTCAGCT3′; Nkx2.1 F: 5′CAGGACACCATGCGGAACAGC3′; Nkx2.1 R: 5′GCCATGTTCTTGCTCACGTCCC3′; Myc F: 5′TCGCTGCTGTCCTCCGAGTCC3′; Myc R: 5′GGTTTGCCTCTTCTCCACAGAC3′; PDGFRα F: 5′GCAGTTGCCTTACGACTCCAGA3′; PDGFRα R: 5′GGTTTGAGCATCTTCACAGCCAC3′; PDGFRβ F: 5′ACTACATCTCCAAAGGCAGCACCT3′; PDGFRβ R: 5′TGTAGAACTGGTCGTTCATGGGCA3′; Axin2 F: 5′ATGGAGTCCCTCCTTACCGCAT3′; Axin2 R: 5′GTTCCACAGGCGTCATCTCCTT3′; Lef1 F: 5′ACTGTCAGGCGACACTTCCATG3′; Lef1 R: 5′GTGCTCCTGTTTGACCTGAGGT3′; Id2 F: 5′TCACCAGAGACCTGGACAGAAC3′; Id2 R: 5′TGCTATCATTCGACATAAGCTCAG3′; Msx2 F: 5′AAGACGGAGCACCGTGGATACA3′; Msx2 R: 5′CGGTTGGTCTTGTGTTTCCTCAG3′; Ptch1 F: 5′GCGCAGTCTTCCTCCTGAAC3′; Ptch1 R: 5′GAGGCCCATCATGCCAAAG3′; Ptch1 probe: 5′CCTGGACGGCCGGGATCATT3′; Gli1 F: 5′GACTGCCGCTGGGATGGTTGCAG3′; Gli1 R: 5′GCGTGAATAGGACTTCCGACAGCCT3′; Gli1 probe: 5′ATTCCCAGGAGCAGCTGGTGCACCACAT3′; Nfκb1 F: 5′ GCTGCCAAAGAAGGACACGACA3′; Nfκb1 R: 5′GGCAGGCTATTGCTCATCACAG3′; Tnf F: 5′GGTGCCTATGTCTCAGCCTCTT3′; Tnf R: 5′GCCATAGAACTGATGAGAGGGAG3′; β-actin F: 5′CTGCCTGACGGCCAGGT3′; β-actin R: 5′TGGAAAAGAGCCTCAGGGC3′; β-actin probe: 5′TCGGAACCGCTCGTTGCCAATAGT 3′; Gapdh F: 5′AGGTTGTCTCCTGCGACTTCA3′; Gapdh R: 5′CCAGGAAATGAGCTTGACAAAGTT3′.

The following primers for human genes were used: SFTPC (SP-C) F: 5′AGCCAGAAACACACGGAGATGGTT3′; SFTPC (SP-C) R: 5′ ATCTTCATGATGTAGCAGCAGGTGCC3′; SCGB1A1 (CC10) F: 5′TCCTCCACCATGAAACTCGCTGT3′; SCGB1A1 (CC10) R: 5′TTCCATGGCAGCCTCATAACTGGA3′; GAPDH F: 5′AAGGTGAAGGTCGGAGTC3′; GAPDH R: 5′GATTTTGGAGGGATCTCG3′. House keeping genes including β-actin and Gapdh were used as internal controls for qPCR.

Acknowledgments

We thank members of the Chuang laboratory for helpful discussions, Chen-Che Huang for technical assistance, Ming-Tseh Lin for advice on tumor histology and Ross Metzger for critical reading of the manuscript.

Funding Statement

The authors have no support or funding to report.

References

1. McErlean A, Ginsberg MS (2011) Epidemiology of lung cancer. Semin Roentgenol 46: 173–177. [PubMed]

2. Ramalingam SS, Owonikoko TK, Khuri FR (2011) Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin 61: 91–112. [PubMed]

3. Murala S, Alli V, Kreisel D, Gelman AE, Krupnick AS (2010) Current status of immunotherapy for the treatment of lung cancer. J Thorac Dis 2: 237–244. [PMC free article] [PubMed]

4. Vallieres E, Peters S, Van Houtte P, Dalal P, Lim E (2011) Therapeutic advances in non-small cell lung cancer. Thorax. [PubMed]

5. Reungwetwattana T, Weroha SJ, Molina JR (2011) Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non-Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer. [PubMed]

6. Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, et al. . (2012) Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol. [PubMed]

7. Greulich H (2010) The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer 1: 1200–1210. [PMC free article] [PubMed]

8. Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD (2010) Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst 102: 1310–1321. [PMC free article] [PubMed]

9. Vahakangas KH, Bennett WP, Castren K, Welsh JA, Khan MA, et al. (2001) p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res 61: 4350–4356. [PubMed]

10. Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, et al. (2004) Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 64: 2307–2316. [PubMed]

11. Kwak I, Tsai SY, DeMayo FJ (2004) Genetically engineered mouse models for lung cancer. Annu Rev Physiol 66: 647–663. [PubMed]

12. Frese KK, Tuveson DA (2007) Maximizing mouse cancer models. Nat Rev Cancer 7: 645–658. [PubMed]

13. de Seranno S, Meuwissen R (2010) Progress and applications of mouse models for human lung cancer. Eur Respir J 35: 426–443. [PubMed]

14. Politi K, Pao W (2011) How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol 29: 2273–2281. [PubMed]

15. Meuwissen R, Berns A (2005) Mouse models for human lung cancer. Genes Dev 19: 643–664. [PubMed]

16. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243–3248. [PubMed]

17. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, et al. (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29: 418–425. [PubMed]

18. Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, et al. (2011) Suppression of lung adenocarcinoma progression by Nkx2–1. Nature 473: 101–104. [PMC free article] [PubMed]

19. Kadara H, Kabbout M, Wistuba II (2012) Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology 17: 50–65. [PubMed]

20. DuPage M, Dooley AL, Jacks T (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4: 1064–1072. PMCID: PMC2757265. [PMC free article] [PubMed]

21. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139. [PubMed]

22. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500. [PubMed]

23. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, et al. (2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20: 1496–1510. [PubMed]

24. Regales L, Balak MN, Gong Y, Politi K, Sawai A, et al. (2007) Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One 2: e810. [PMC free article] [PubMed]

25. Morrisey EE, Hogan BL (2010) Preparing for the first breath: genetic and cellular mechanisms in lung development. Dev Cell 18: 8–23. [PubMed]

26. Sutherland KD, Berns A (2010) Cell of origin of lung cancer. Mol Oncol 4: 397–403. [PubMed]

27. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, et al. (2005) Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823–835. [PubMed]

28. Rawlins EL, Okubo T, Xue Y, Brass DM, Auten RL, et al. (2009) The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell 4: 525–534. [PMC free article] [PubMed]

29. Joyner AL (2000) Gene targeting: a practical approach, second edition (Oxford University Press).

30. Andreeva AV, Kutuzov MA, Voyno-Yasenetskaya TA (2007) Regulation of surfactant secretion in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 293: L259–271. [PubMed]

31. Danielian PS, Muccino D, Rowitch DH, Michael SK, McMahon AP (1998) Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase. Curr Biol 8: 1323–1326. [PubMed]

32. Soriano P (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21: 70–71. [PubMed]

33. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L (2007) A global double-fluorescent Cre reporter mouse. Genesis 45: 593–605. [PubMed]

34. Branda CS, Dymecki SM (2004) Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev Cell 6: 7–28. [PubMed]

35. Nagy A, Gertsenstein M, Vintersten K, Behringer R (2003) Manipulating the Mouse Embryo: A Laboratory Manual, Third Edition (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press).

36. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10: 760–774. [PMC free article] [PubMed]

37. da Cunha Santos G, Shepherd FA, Tsao MS (2011) EGFR mutations and lung cancer. Annu Rev Pathol 6: 49–69. [PubMed]

38. Eliasz S, Liang S, Chen Y, De Marco MA, Machek O, et al. (2010) Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene 29: 2488–2498. [PMC free article] [PubMed]

39. Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, et al. (2011) The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest 121: 1373–1385. [PMC free article] [PubMed]

40. Xu X, Rock JR, Lu Y, Futtner C, Schwab B, et al. (2012) Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. Proc Natl Acad Sci U S A 109: 4910–4915. [PubMed]

41. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, et al. (2005) The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65: 10280–10288. [PubMed]

42. Chapman HA, Li X, Alexander JP, Brumwell A, Lorizio W, et al. (2011) Integrin alpha6beta4 identifies an adult distal lung epithelial population with regenerative potential in mice. J Clin Invest 121: 2855–2862. [PMC free article] [PubMed]

43. Kitamura H, Kameda Y, Ito T, Hayashi H, Nakamura N, et al. (1997) Cytodifferentiation of atypical adenomatous hyperplasia and bronchioloalveolar lung carcinoma: immunohistochemical and ultrastructural studies. Virchows Arch 431: 415–424. [PubMed]

44. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175–180. [PubMed]

45. Rodriguez CI, Buchholz F, Galloway J, Sequerra R, Kasper J, et al. (2000) High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet 25: 139–140. [PubMed]

46. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG (2005) Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 33: e36. [PMC free article] [PubMed]

47. Glasser SW, Burhans MS, Korfhagen TR, Na CL, Sly PD, et al. (2001) Altered stability of pulmonary surfactant in SP-C-deficient mice. Proc Natl Acad Sci U S A 98: 6366–6371. [PubMed]

Articles from PLoS ONE are provided here courtesy of
Public Library of Science